Skip to content
Peptide research

SS-31 (Elamipretide)

Also known as Bendavia · MTP-131 · Forzinity
Category
Longevity & Anti-Aging
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

A mitochondria-targeted peptide marketed to reverse age-related decline in cellular energy, heart, muscle, eye, and kidney function. It stabilizes cardiolipin, and human evidence gives medium confidence to improved ATP production, while cardiac, muscle, retinal, and kidney benefits rest on thin, low-confidence trials. Injection reactions are common and pregnancy safety unknown. On September 19, 2025, the FDA granted Forzinity (elamipretide) accelerated approval only for muscle strength in Barth syndrome, a rare mitochondrial disease, in patients weighing at least 30 kg. Aging and wellness uses are unapproved, and products sold online outside the approved drug are unregulated.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Reversal of age-related mitochondrial dysfunction and improved ATP production

    Medium

    Small human trial showed improved muscle ATP production, backed by extensive animal data.

  • Reversal of age-related cardiac diastolic dysfunction

    Low

    Reversed diastolic dysfunction in aged mice across several studies, not tested in aging humans.

  • Improved skeletal muscle performance and exercise tolerance during aging

    Low

    Animal studies show improved muscle energetics, but a human trial missed the exercise function endpoint.

Evidence limits

Evidence Level
Phase 2-3

SS-31's clinical evidence is the most extensive of any mitochondria-targeted peptide. The TAZPOWER trial in Barth syndrome (Phase 2/3 with 168-week open-label extension, 12 patients) achieved FDA accelerated approval based on >45% improvement in knee extensor muscle strength and sustained improvements in 6MWT, cardiac function, and fatigue scores. The MMPOWER-3 trial (218 PMM patients, Phase 3) failed co-primary endpoints but revealed a significant 6MWT improvement in the nDNA variant subgroup, suggesting elamipretide is effective when ETC protein subunits are structurally normal but membrane organization is disrupted. The ReCLAIM-2 trial (176 dry AMD patients, Phase 2) did not meet primary endpoints but showed 43-47% reduction in ellipsoid zone attenuation progression and improved low-light vision. The PROGRESS-HF trial (71 HFrEF patients, Phase 2) and EMBRACE-STEMI trial (STEMI patients, Phase 2a) failed primary endpoints. Roshanravan et al. 2021 (39 older adults, RCT) demonstrated improved mitochondrial ATP production after a single dose. The preclinical evidence base is exceptionally strong, with consistent reversal of age-related mitochondrial dysfunction across cardiac, skeletal muscle, renal, and retinal models in aged mice.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Severe renal impairment

    Moderate

    Renal-impairment pharmacokinetics have been characterized. Severe renal impairment increases exposure; dialysis has not been studied.

General cautions

  • Pregnancy

    Absolute

    Pregnancy — human safety data are unavailable; animal reproductive studies found no adverse developmental outcomes at tested exposures. Pregnancy is not an absolute contraindication. The labeled contraindication is serious hypersensitivity to elamipretide or FORZINITY excipients.

Risk summary(7)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Injection site reactions

    High
  • Hypersensitivity reactions

    Moderate
  • Headache, dizziness, nausea, abdominal pain, and fatigue

    Low
  • Renal excretion considerations

    Moderate
  • Benzyl alcohol preservative in FORZINITY formulation

    Moderate
  • Pregnancy and lactation safety unknown

    Moderate
  • Unregulated products sold online: purity and IP concerns

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.